NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled
NCT02178722 2022-02-14Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersIncyte CorporationPhase 1/2 Completed444 enrolled 19 charts
NCT03538028 2020-10-30A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesIncyte CorporationPhase 1 Completed22 enrolled